Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot/Feasibility Phase I Study of Bendamustine, Rituximab and Lenalidomide in Patients With Refractory/Relapsed Indolent NHL

NCT01429025 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT01429025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01429025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot/Feasibility Phase I Study of Bendamustine, Rituximab and Lenalidomide in Patients With Refractory/Relapsed Indolent NHL
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2012
Completion date
July 1, 2019
Enrollment
26 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

refractory/relapsed indolent non-hodgkin lymphoma